Respiratory and thoracic cancers:
Indications for: Etoposide Capsules
Small cell lung cancer.
Round dose to nearest 50mg increment. Range: 70mg/m2 per day for 4 days to 100mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment (CrCl ≤50mL/min): reduce dose (see literature). Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.
Etoposide Capsules Warnings/Precautions:
Monitor blood (esp CBC/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Pregnancy (Cat.D); nursing mothers: not recommended.
Etoposide Capsules Classification:
Etoposide Capsules Interactions:
Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.
GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; hypersensitivity reactions, acute leukemia (rare); others.
Formerly known under the brand name VePesid.